Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
1
Issued Date
2024-11-01
Resource Type
ISSN
22876375
eISSN
22877029
Scopus ID
2-s2.0-85212606911
Journal Title
Journal of Bone Metabolism
Volume
31
Issue
4
Start Page
264
End Page
278
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Bone Metabolism Vol.31 No.4 (2024) , 264-278
Suggested Citation
Srisuwarn P., Eastell R., Salam S. Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease. Journal of Bone Metabolism Vol.31 No.4 (2024) , 264-278. 278. doi:10.11005/jbm.24.789 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102543
Title
Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
Author(s)
Corresponding Author(s)
Other Contributor(s)
Abstract
Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification, and bone abnormalities (renal osteodystrophy [ROD]). Bone fragility in CKD occurs due to low bone mass and poor bone quality, and patients with CKD have higher fracture and mortality rates. Bone histomorphometry is the gold standard for ROD diagnosis; however, it is labor-intensive and expensive. The Kidney Disease Improving Global Outcomes clinical practice guidelines on CKD-MBD suggest serum parathyroid hormone (PTH) and bone-specific alkaline phosphatase (bone ALP) for predicting bone turnover in ROD. In this review, we focus on the role of PTH and bone turnover markers, intact procollagen type N-terminal propeptide of type I collagen, bone ALP, and tartrate-resistant acid phosphatase 5b in diagnosing ROD, predicting fractures, and guiding treatment in patients with CKD.